Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Atopic Dermatitis: Incorporating New Non-steroidal Topicals into Practice
Description
The presentation discusses the integration of new non-steroidal topical treatments for atopic dermatitis into clinical practice. The speaker, a physician specializing in dermatology, emphasizes the importance of topical care, which includes the use of traditional topical corticosteroids, calcineurin inhibitors, and newer non-steroidal agents. Various newly approved or upcoming medications are explored, including topical ruxolitinib cream and rifamilast, highlighting their efficacy in clinical trials. Ruxolitinib has shown significant improvement in reducing itch and skin symptoms, with effective long-term outcomes reported in trials. The speaker addresses the growing skepticism surrounding topical corticosteroids, particularly due to misinformation propagated via social media. Concerns regarding safety and patient adherence are also discussed. The evolving treatment landscape shows promise with emerging agents like tofacitinib and others aimed at pediatric populations, demonstrating favorable safety and effectiveness profiles. The presentation underscores the need for tailored regimen approaches depending on individual patient circumstances while managing both efficacy and the practicalities of treatment in clinical settings. Overall, continuous advancements in atopic dermatitis management are slowly refining therapeutic strategies for optimal patient outcomes.
View moreConclusions
- Topical treatments continue to play a crucial role in managing atopic dermatitis (AD).
- New non-steroidal options, such as topical ruxolitinib and tapinarof, show promising efficacy and safety in pediatric AD.
- Ruxolitinib cream demonstrated effective long-term disease control with improved itch relief and consistency in results across studies.
- Tapinarof provides significant benefits in reducing inflammation and enhancing skin barrier function in AD patients.
- Crisaborole ointment proved effective as a maintenance therapy, extending flare-free intervals for AD patients.
- The increasing awareness of safety concerns surrounding topical corticosteroids complicates treatment approaches, highlighting the need for effective alternatives.
- AAD guidelines endorse the use of topical non-steroidal treatments alongside traditional therapies for better patient outcomes.
- There is a trend towards developing maintenance regimens with non-steroidal agents to achieve remission in AD patients.
- Overall, the ongoing evolution of non-steroidal agents presents new opportunities for improved management of atopic dermatitis.
- Kleinman E, Laborada J, Metterle L, Eichenfield LF. Am J Clin Dermatol. 2022 Sep;23(5):595-603. doi: 10.1007/s40257-022-00712-0
- Papp K, et al. RAD June 2021 Virtual Conference, #511. Sponsored by Incyte Corporation
- Kim BS et al. J Allergy Clin Immunol 202;145:572-582
- Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF et al. J Am Acad Dermatol 2021 Oct:85:4:863-72
- Leung DYM, et al. Ann Allergy Asthma Immunol. 2022;S1081-1206(22)02048-8
- Eichenfield L, et al. EADV 2023, D3T01.3L. Sponsored by Incyte Corporation
- Eichenfield et. Al Am J Clin Dermatol; 2023;https://doi.org/10.1007/s40257-023000780-w
- Silverberg JI, et al. EADV 2023, D1T01.1G
- Stein-Gold L et al. Poster AAD 2024
- Paller AS, Eichenfield LF et al. Pediatrics. 2008 Dec;122(6):e1210-8. doi: 10.1542/peds.2008-1343. Epub 2008 Nov 17. PMID: 19015204.
- Wiren K et al. J Eur Acad Dermatol Venereol. 2009 Nov;23(11):1267-72
- Angelova-Fischer I et a. Acta Derm Venereol. 2018 Apr 27;98(5):517-523. doi: 10.2340/00015555-2757.
- Tiplica GS et al. Pediatr Dermatol. 2017 May;34(3):282-289. doi: 10.1111/pde.13113